Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug survival of omalizumab in atopic asthma: Impact of clinical and genetic variables.

Human vaccines & immunotherapeutics - 1 Dec 2025

Rojo-Tolosa Susana, Caballero-Vázquez Alberto, Pineda-Lancheros Laura E, Sánchez-Martínez José A, González-Gutiérrez María V, Jiménez-Gálvez Gonzalo, Jiménez-Morales Alberto, Morales-García Concepción

Abstract excerpt

It is estimated that 40-50% of severe asthma has an atopic basis, representing a clinical challenge and a significant economic burden for healthcare systems. The most effective treatment has emerged with the use of biologic therapies such as omalizumab; however, the rate of therapy switching due to loss of efficacy is high, which has a negative impact on the healthcare system. The aim was to evaluate the...

Read the complete abstract on PubMed

Topics

Humans
Asthma
Omalizumab
Female
Male
Retrospective Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Adult

Anti-Asthmatic Agents

Polymorphism, Single Nucleotide

Treatment Outcome

Aged

Tertiary Care Centers

Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 40189906
DOI: 10.1080/21645515.2025.2488557
PMCID: PMC12054927

Genes

FCGR3A
C3
FCER1A
FCGR2A
FCGR2B
GATA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug survival of omalizumab in atopic asthma: Impact of clinical and genetic variables.PMID 40189906Read ↗

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.Semantic proximity Read ↗

The efficacy of omalizumab treatment in patients with non-atopic severe asthmaSemantic proximity Read ↗

Influence of effective omalizumab treatment on eosinophils in allergic asthma with comorbiditiesSemantic proximity Read ↗

Biological Therapy Persistence in Severe Asthma: Real-World Evidence Beyond Fixed Follow-Up AnalysisSemantic proximity Read ↗

Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype.Semantic proximity Read ↗

Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.Semantic proximity Read ↗

SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.Semantic proximity Read ↗

Efficacy and Safety of Add-On Omalizumab in 4-6-Year-Old Children with Uncontrolled Allergic Asthma: A 52-Week Retrospective StudySemantic proximity Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Single cell RNA-seq discovery of blood biomarkers predicting treatment outcome in severe asthma patientsSemantic proximity Read ↗

Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of OmalizumabSemantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.